What's New with the St George's Respiratory Questionnaire and Why Do We Care?
作者信息
Hardin Megan, Rennard Stephen I
机构信息
Clinical Discovery Unit, Early Clinical Discovery, AstraZeneca, Waltham, Massachusetts.
Clinical Discovery Unit, Early Clinical Discovery, AstraZeneca, Cambridge, United Kingdom.
出版信息
Chronic Obstr Pulm Dis. 2017 Apr 3;4(2):83-86. doi: 10.15326/jcopdf.4.2.2017.0139.
Abstract
摘要
相似文献
1
What's New with the St George's Respiratory Questionnaire and Why Do We Care?圣乔治呼吸问卷有哪些新变化，以及我们为何要关注？
Chronic Obstr Pulm Dis. 2017 Apr 3;4(2):83-86. doi: 10.15326/jcopdf.4.2.2017.0139.
2
The COPD Biomarkers Qualification Consortium St George's Respiratory Questionnaire Manuscripts: Output of a Consortium to Advance Drug Development.慢性阻塞性肺疾病生物标志物鉴定联合会圣乔治呼吸问卷手稿：推进药物研发的联合会成果
Chronic Obstr Pulm Dis. 2017 Feb 28;4(2):109-111. doi: 10.15326/jcopdf.4.2.2017.0127.
3
The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset.慢性阻塞性肺疾病生物标志物资格认定联盟数据库：圣乔治呼吸问卷数据集的基线特征
Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123. doi: 10.15326/jcopdf.4.2.2017.0128.
4
St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.圣乔治呼吸问卷评分可预测慢性阻塞性肺疾病患者的预后：慢性阻塞性肺疾病生物标志物鉴定联盟数据库中个体患者数据的分析
Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.
5
Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.在慢性阻塞性肺疾病（COPD）患者中使用长效支气管扩张剂的试验中，基线严重程度作为圣乔治呼吸问卷评分变化的预测指标。
Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.
6
Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.使用圣乔治呼吸问卷对慢性阻塞性肺疾病治疗效果的反应者分析
Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.
7
The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD?慢性阻塞性肺疾病评估测试和圣乔治呼吸问卷：它们在慢性阻塞性肺疾病患者中是否等效？
Int J Chron Obstruct Pulmon Dis. 2016 Jul 7;11:1543-51. doi: 10.2147/COPD.S104947. eCollection 2016.
8
American translation, modification, and validation of the St. George's Respiratory Questionnaire.圣乔治呼吸问卷的美国版翻译、修改及验证
Clin Ther. 2000 Sep;22(9):1121-45. doi: 10.1016/S0149-2918(00)80089-2.
9
Interpretation of quality of life scores from the St George's Respiratory Questionnaire.圣乔治呼吸问卷生活质量评分的解读
Eur Respir J. 2002 Mar;19(3):405-13. doi: 10.1183/09031936.02.00213202.
引用本文的文献
1
Comparison of the efficacy of noninvasive positive pressure ventilation combined with and without budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in the treatment of acute exacerbations of Chronic Obstructive Pulmonary Disease.无创正压通气联合与不联合布地奈德/格隆溴铵/富马酸福莫特罗定量吸入器治疗慢性阻塞性肺疾病急性加重期的疗效比较
Pak J Med Sci. 2025 Apr;41(4):1157-1163. doi: 10.12669/pjms.41.4.11507.
2
Impact of Dyspnea on Adults With Respiratory Symptoms Without a Defined Diagnosis.呼吸困难对未明确诊断的有呼吸道症状的成年人的影响。
Chest. 2024 Dec;166(6):1296-1308. doi: 10.1016/j.chest.2024.07.183. Epub 2024 Sep 4.
3
A primary care medical home approach to pulmonary rehabilitation.一种采用初级保健医疗之家模式的肺康复方法。
Can J Respir Ther. 2021 Dec 23;57:161-166. doi: 10.29390/cjrt-2021-040. eCollection 2021.
4
Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives.药物开发指导治疗慢性阻塞性肺疾病的综述：美国和欧盟的观点。
Clin Pharmacol Ther. 2019 Dec;106(6):1222-1235. doi: 10.1002/cpt.1540. Epub 2019 Jul 23.
5
Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies.雾化吸入格隆溴铵对中重度至极重度慢性阻塞性肺疾病患者健康相关生活质量的改善作用：来自GOLDEN研究的证据
Chronic Obstr Pulm Dis. 2018 Jun 6;5(3):193-207. doi: 10.15326/jcopdf.5.3.2017.0178.
6
Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).慢性气道炎症性疾病气道黏液高分泌的管理：中国专家共识（英文版）
Int J Chron Obstruct Pulmon Dis. 2018 Jan 30;13:399-407. doi: 10.2147/COPD.S144312. eCollection 2018.
7
Airway clearance techniques for bronchiectasis.支气管扩张症的气道廓清技术
Cochrane Database Syst Rev. 2015 Nov 23;2015(11):CD008351. doi: 10.1002/14651858.CD008351.pub3.
本文引用的文献
1
Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials.慢性阻塞性肺疾病（COPD）试验中作为健康状况治疗反应决定因素的社会经济地位
Chronic Obstr Pulm Dis. 2017 Apr 1;4(2):150-158. doi: 10.15326/jcopdf.4.2.2017.0132.
2
St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.圣乔治呼吸问卷评分可预测慢性阻塞性肺疾病患者的预后：慢性阻塞性肺疾病生物标志物鉴定联盟数据库中个体患者数据的分析
Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.
3
Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.在慢性阻塞性肺疾病（COPD）患者中使用长效支气管扩张剂的试验中，基线严重程度作为圣乔治呼吸问卷评分变化的预测指标。
Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.
4
Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.使用圣乔治呼吸问卷对慢性阻塞性肺疾病治疗效果的反应者分析
Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.
5
The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset.慢性阻塞性肺疾病生物标志物资格认定联盟数据库：圣乔治呼吸问卷数据集的基线特征
Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123. doi: 10.15326/jcopdf.4.2.2017.0128.
6
The COPD Biomarkers Qualification Consortium St George's Respiratory Questionnaire Manuscripts: Output of a Consortium to Advance Drug Development.慢性阻塞性肺疾病生物标志物鉴定联合会圣乔治呼吸问卷手稿：推进药物研发的联合会成果
Chronic Obstr Pulm Dis. 2017 Feb 28;4(2):109-111. doi: 10.15326/jcopdf.4.2.2017.0127.
7
Interpreting patient-reported outcomes from clinical trials in COPD: a discussion.解读慢性阻塞性肺疾病临床试验中患者报告的结局：一场讨论
Int J Chron Obstruct Pulmon Dis. 2016 Dec 7;11:3069-3078. doi: 10.2147/COPD.S117378. eCollection 2016.
8
Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.肺功能正常的吸烟者症状的临床意义
N Engl J Med. 2016 May 12;374(19):1811-21. doi: 10.1056/NEJMoa1505971.
9
Innovation in the pharmaceutical industry: New estimates of R&D costs.制药行业的创新：研发成本的新估计
J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12.
10
Minimal clinically important differences in pharmacological trials.药理学试验中的最小临床重要差异。
Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5. doi: 10.1164/rccm.201310-1863PP.
Zotero 插件